Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Bolsters Stem Cell Rules, Allows Broader Gene Therapy

This article was originally published in PharmAsia News

Executive Summary

South Korea revised a set of rules in December to beef up its regulation of the stem cell and gene therapy sectors, which are seen as part of the country's new growth engines. Under the changes, the government will require stem cell therapy companies to submit risk management plans when they seek product approvals and will introduce a long-term tracking system. The scope of allowable gene therapy research will also be broadened following industry calls.

You may also be interested in...

SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership

Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.

Daewoong Readies Diabetes Contender Enavogliflozin, Aiming For '23 Launch

With multiple South Korean INDs to begin Phase III trials with its SGLT-2 inhibitor enavogliflozin, Daewoong is aiming to speed domestic and global development of the potentially best-in-class drug for type 2 diabetes.

Asia Deal Watch: Bone Therapeutics Licenses Bone Cell Therapy Tech To Two Asian Firms

Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts